These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

822 related items for PubMed ID: 14666732

  • 1. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M.
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [Abstract] [Full Text] [Related]

  • 2. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
    Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y.
    Cancer Res; 2002 Oct 15; 62(20):5813-7. PubMed ID: 12384543
    [Abstract] [Full Text] [Related]

  • 3. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
    Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A, Toge T.
    Anticancer Res; 2005 Oct 15; 25(2A):827-32. PubMed ID: 15868915
    [Abstract] [Full Text] [Related]

  • 4. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
    Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M.
    Clin Cancer Res; 2007 Mar 15; 13(6):1875-82. PubMed ID: 17363544
    [Abstract] [Full Text] [Related]

  • 5. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
    Kasuya K, Shimazu M, Suzuki M, Itoi T, Aoki T, Tsuchida A.
    Int J Mol Med; 2010 Feb 15; 25(2):209-15. PubMed ID: 20043129
    [Abstract] [Full Text] [Related]

  • 6. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA.
    Semin Oncol; 1999 Aug 15; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [Abstract] [Full Text] [Related]

  • 7. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Ménard S, Costa A, Fagnoni FF.
    Cancer Res; 2007 Dec 15; 67(24):11991-9. PubMed ID: 18089830
    [Abstract] [Full Text] [Related]

  • 8. Stimulated γδ T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer.
    Capietto AH, Martinet L, Fournié JJ.
    J Immunol; 2011 Jul 15; 187(2):1031-8. PubMed ID: 21670311
    [Abstract] [Full Text] [Related]

  • 9. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.
    zum Büschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H.
    Cancer Res; 2002 Apr 15; 62(8):2244-7. PubMed ID: 11956077
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
    Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA.
    Eur J Immunol; 2001 Oct 15; 31(10):3016-25. PubMed ID: 11592078
    [Abstract] [Full Text] [Related]

  • 11. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
    Clémenceau B, Gallot G, Vivien R, Gaschet J, Campone M, Vié H.
    J Immunother; 2006 Oct 15; 29(1):53-60. PubMed ID: 16365600
    [Abstract] [Full Text] [Related]

  • 12. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
    Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE.
    Ann Surg Oncol; 2006 Aug 15; 13(8):1085-98. PubMed ID: 16865596
    [Abstract] [Full Text] [Related]

  • 13. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
    Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J.
    Cancer Res; 2001 Jun 15; 61(12):4744-9. PubMed ID: 11406546
    [Abstract] [Full Text] [Related]

  • 14. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S.
    Semin Oncol; 1999 Aug 15; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [Abstract] [Full Text] [Related]

  • 15. [Herceptin and its therapeutic strategy in patients with breast cancer overexpressing HER2].
    Tajima T, Suzuki Y, Tokuda Y.
    Gan To Kagaku Ryoho; 2002 Jul 15; 29(7):1132-7. PubMed ID: 12145992
    [Abstract] [Full Text] [Related]

  • 16. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
    Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J.
    Cancer Res; 2009 Oct 15; 69(20):8058-66. PubMed ID: 19826050
    [Abstract] [Full Text] [Related]

  • 17. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C, Watanabe M, Singh B, Walker M, Kufe DW, Hayes DF.
    Cancer Res; 2001 May 15; 61(10):4061-5. PubMed ID: 11358826
    [Abstract] [Full Text] [Related]

  • 18. [Combination immunotherapy using autologous tumor-stimulated lymphocytes and trastuzumab (Herceptin) for the patients with recurrent breast cancer].
    Toh U, Fujii T, Miwa K, Yokoyama G, Yamaguchi M, Kawamura D, Machida E, Shirouzu K, Yamana H.
    Gan To Kagaku Ryoho; 2005 Oct 15; 32(11):1789-91. PubMed ID: 16315942
    [Abstract] [Full Text] [Related]

  • 19. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP.
    Clin Cancer Res; 2002 May 15; 8(5):1271-9. PubMed ID: 12006548
    [Abstract] [Full Text] [Related]

  • 20. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
    Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A.
    J Clin Oncol; 2008 Apr 10; 26(11):1789-96. PubMed ID: 18347005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.